{"id":3096,"date":"2018-08-22T15:27:10","date_gmt":"2018-08-22T09:57:10","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3096"},"modified":"2021-07-24T12:57:02","modified_gmt":"2021-07-24T07:27:02","slug":"snippet-cancer","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/snippet-cancer","title":{"rendered":"Snippet"},"content":{"rendered":"

HOA Puts into Operation of Updated CyberKnife Version <\/strong><\/h3>\n

Cancer<\/strong> patients now have a solid reason to cheer, as US-based Hematology-Oncology<\/a> Associates<\/strong> (HOA) lately came up with the new CyberKnife<\/strong> (CK) and replaced their original CyberKnife with an updated that is even more precise, fast and effective, and known as the CyberKnife M6 Series that has remarkable pain relief.\u00a0 The new CyberKnife (CK) is the only FDA<\/strong> approved completely Robotic Stereotactic Radiosurgery System<\/span><\/em> available in the world that targets and destroys previously inaccessible tumors<\/strong>.\u00a0 The CyberKnife M6 Series model is endowed with the notable feature of delivering doses with sub-millimeter accuracy, to both static as well as moving targets. Its radiation dose adjusts automatically in the real-time to respiration as well as other changes in tumor position. Moreover, the updated version of the robotic radiosurgery system has anatomy-specific tracking and treatment delivery solutions for brain, spine, lung and prostate. It has become a standard option for prostate cancer treatment and unlike conventional radiation\/IMRT, only the CyberKnife has a five-day treatment regime instead of a 45-day treatment regime for prostate cancer<\/strong><\/a>.\u00a0It cuts down on co-pays and the overall costs of treating prostate cancer. In addition, over 9 years of data shows profiles on sparing healthy tissues, namely rectum and bladder, to be better than IMRT<\/strong> when the CyberKnife was used for prostate treatment.\u00a0In essence, the CyberKnife mode of cancer treatment proves to be higher in efficacy and at the same time reduces the treatment time.<\/p>\n","protected":false},"excerpt":{"rendered":"

HOA Puts into Operation of Updated CyberKnife Version Cancer patients now have a solid reason to cheer, as US-based Hematology-Oncology Associates (HOA) lately came up with the new CyberKnife (CK) and replaced their original CyberKnife with an updated that is even more precise, fast and effective, and known as the CyberKnife M6 Series that has […]<\/p>\n","protected":false},"author":1,"featured_media":3097,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[137,1704,1708,704,1703,1702,1706,380,427,498,1707,1705,593],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-3096","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-cancer","tag-cyberknife","tag-cyberknife-m6-series-model","tag-fda","tag-hematology-oncology-associates","tag-hoa","tag-imrt","tag-market-reports","tag-oncology","tag-prostate-cancer","tag-robotic-stereotactic-radiosurgery-system","tag-tumor","tag-us-food-and-drug-administration-fda","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nSnippet : Cancer - DelveInsight Business Research LLP..<\/title>\n<meta name=\"description\" content=\"Cancer patients now have a solid reason to cheer, as US-based Hematology-Oncology Associates (HOA) lately came up with the new CyberKnife (CK) and\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/snippet-cancer\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Snippet : Cancer - DelveInsight Business Research LLP..\" \/>\n<meta property=\"og:description\" content=\"Cancer patients now have a solid reason to cheer, as US-based Hematology-Oncology Associates (HOA) lately came up with the new CyberKnife (CK) and\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/snippet-cancer\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-08-22T09:57:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09021352\/cancer.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Snippet : Cancer - DelveInsight Business Research LLP..","description":"Cancer patients now have a solid reason to cheer, as US-based Hematology-Oncology Associates (HOA) lately came up with the new CyberKnife (CK) and","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/snippet-cancer","og_locale":"en_US","og_type":"article","og_title":"Snippet : Cancer - DelveInsight Business Research LLP..","og_description":"Cancer patients now have a solid reason to cheer, as US-based Hematology-Oncology Associates (HOA) lately came up with the new CyberKnife (CK) and","og_url":"https:\/\/www.delveinsight.com\/blog\/snippet-cancer","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-08-22T09:57:10+00:00","article_modified_time":"2021-07-24T07:27:02+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09021352\/cancer.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/snippet-cancer","url":"https:\/\/www.delveinsight.com\/blog\/snippet-cancer","name":"Snippet : Cancer - DelveInsight Business Research LLP..","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/snippet-cancer#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/snippet-cancer#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09021352\/cancer.jpg","datePublished":"2018-08-22T09:57:10+00:00","dateModified":"2021-07-24T07:27:02+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Cancer patients now have a solid reason to cheer, as US-based Hematology-Oncology Associates (HOA) lately came up with the new CyberKnife (CK) and","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/snippet-cancer"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/snippet-cancer#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09021352\/cancer.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09021352\/cancer.jpg","width":640,"height":400,"caption":"Cancer"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09021352\/cancer-300x188.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">CyberKnife<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">CyberKnife M6 Series model<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Hematology-Oncology Associates<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">HOA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">IMRT<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Market Reports<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Oncology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Prostate Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Robotic Stereotactic Radiosurgery System<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Tumor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">US Food and Drug Administration (FDA)<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">CyberKnife<\/span>","<span class=\"advgb-post-tax-term\">CyberKnife M6 Series model<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Hematology-Oncology Associates<\/span>","<span class=\"advgb-post-tax-term\">HOA<\/span>","<span class=\"advgb-post-tax-term\">IMRT<\/span>","<span class=\"advgb-post-tax-term\">Market Reports<\/span>","<span class=\"advgb-post-tax-term\">Oncology<\/span>","<span class=\"advgb-post-tax-term\">Prostate Cancer<\/span>","<span class=\"advgb-post-tax-term\">Robotic Stereotactic Radiosurgery System<\/span>","<span class=\"advgb-post-tax-term\">Tumor<\/span>","<span class=\"advgb-post-tax-term\">US Food and Drug Administration (FDA)<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Aug 22, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Aug 22, 2018 3:27 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3096"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3096\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3097"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3096"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3096"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3096"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3096"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}